Arax Advisory Partners’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Arax Advisory Partners’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$50K	Buy	+4,625	New	+$49.7K	﹤0.01%	3316

Other funds holding DMAA

Mizuho Securities USA New York $6.3B AUM 30.7% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return

First Trust Capital Management Chicago, Illinois $2.08B AUM 59.2% 1-Year Est. Return

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 22.91% 1-Year Est. Return

RLH Capital Great Neck, New York $277M AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Dakota Wealth Management Palm Beach Gardens, Florida $5.38B AUM 27.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Arax Advisory Partners's DMAA Position: Q3 2026 in Review

Arax Advisory Partners opened a new position in Drugs Made In America Acquisition Corp (DMAA) in Q3 2026: 4,625 shares worth $50K. The stake represents ﹤0.01% of the portfolio and ranks #3316 among its holdings.

10 funds tracked by Wall St. Rank hold DMAA as of Q3 2026.

Arax Advisory Partners held 4,625 shares of Drugs Made In America Acquisition Corp worth $50K as of Q3 2026.
Drugs Made In America Acquisition Corp was a new Arax Advisory Partners position in Q3 2026.
Drugs Made In America Acquisition Corp made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #3316 holding.
10 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.